Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The study will look at the effect of 30 days of treatment of 15 diabetics with proteinuria
with N-acetylcysteine ( Mucomyst ) at a dose of 1 gm twice a day by mouth. The primary
outcome that will be measured is change in the oxidant stress as measurable by changes in the
serum level of isoprostane, Glutathione peroxidase, aconitase and Total oxidant stress.
Secondary outcomes measured will be changes in proteinuria and kidney function as measured by
spot urine pr/cr and estimated GFR by MDRD formula.
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development